Yumi Hidaka
University of Miyazaki
14 Papers
8 Citations
Yumi Hidaka is an academic researcher from University of Miyazaki. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination
Norihide Jo,Yumi Hidaka,Osamu Kikuchi,Masaru Fukahori,Takashi Sawada,Masahiko Aoki,Masayuki Yamamoto,Miki Nagao,Satoshi Morita,Takako Nakajima,Manabu Muto,Yoko Hamazaki +11 more
TL;DR: In this paper , older adults had fewer vaccine-induced spike-specific CD4 + T cells including CXCR3 + circulating follicular helper T cells and the T H 1 subset of T cells after the first dose, which correlated with their lower peak IgG levels and fewer systemic adverse effects after the second dose compared with younger adults.
Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats.
Masashi Nagata,Yumi Hidaka,Muneaki Hidaka,Yohei Kawano,Tomomi Iwakiri,Manabu Okumura,Kazuhiko Arimori +6 more
TL;DR: The effect of acute hepatic failure on the first‐pass effect of 5‐fluorouracil in rats is investigated in rats to increase treatment efficacy and reduce systemic toxicity.
6
Electromagnetic navigation bronchoscopy-guided radiofrequency identification marking in wedge resection for fluoroscopically invisible small lung lesions.
Yojiro Yutaka,Toshihiko Sato,Yumi Hidaka,Takao Kato,Hidenao Kayawake,Satona Tanaka,Yoshito Yamada,Akihiro Ohsumi,D. Nakajima,Masatsugu Hamaji,Toshi Menju,Hiroshi Date +11 more
TL;DR: In this article , the authors developed a novel wireless localization technique after electromagnetic navigation bronchoscopy-guided radiofrequency identification marker placement for fluoroscopically invisible small lung lesions.
6
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).
Nobuyuki Katakami,Takashi Nishimura,Yumi Hidaka,Akito Hata,Kazumi Nishino,Masahide Mori,Tomonori Hirashima,Naoto Takase,Toshihiko Kaneda,Hisashi Ohnishi,Satoshi Morita,Yukimasa Hatachi +11 more
TL;DR: The optimal dosing interval of Zoledronic acid (ZA) for patients with lung cancer is uncertain this paper , and an 8-week ZA interval does not increase the risk of SRE in patients with bone metastasis from lung cancer.
3
Development of Novel Layered Polyglycolic Acid Sheet for Regeneration of Critical-Size Defect in Rat Trachea.
Yoshitake Murata,Yojiro Yutaka,Rieko Hirata,Yumi Hidaka,Masatsugu Hamaji,Akihiro Yoshizawa,Yoshiyuki Ohsugi and Tadamitsu Kishimoto,Koichi Omori,Hiroshi Date +8 more
TL;DR: In this paper , a novel layered polyglycolic acid material was used to cover the central airway and examined its morphologic traits and functional performance as a potential tracheal replacement.
3